FDA Issues News Release on Expanded Use of Gardasil 9

Oct 12, 2018 | Kimberly Sharpe-Scott

On October 5, 2018, the U.S. Food and Drug Administration (FDA) issued a news release to announce the administration’s approval of the expanded use of Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) to include women and men aged 27 through 45 years of age. Gardasil 9, which protects against nine HPV types, was originally approved by the FDA in 2014 for use in males and females aged 9 through 26 years.

Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research, stated, “Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range. The Centers for Disease Control and Prevention has stated that HPV vaccination prior to becoming infected with the HPV types covered by the vaccine has the potential to prevent more than 90 percent of these cancers, or 31,200 cases every year, from ever developing.”

For more information, view the news release, FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. To access additional information regarding Gardasil 9 and recent updates, visit


About Kimberly Sharpe-Scott

More posts by Kimberly Sharpe-Scott

Related Posts

Coronavirus COVID 19
  • COVID-19
  • Tools & Resources
  • Research & Reports

Environmental Health & COVID-19 Resource Roundup:...

As part of the National Association of County and City Health Officials’...

Jan 19, 2021 | Anu Varma

Environmental Health & COVID-19 Resource Roundup:...

Viral hepatitis logo
  • HIV, STI, & Viral Hepatitis

HHS Releases National Plan for Hepatitis Elimination

On January 7, 2021, the U.S. Department of Health and Human Services (HHS)...

Jan 19, 2021 | Kat Kelley

HHS Releases National Plan for Hepatitis Elimination

Si neisseria gonorrhoeae
  • Funding Opportunity
  • HIV, STI, & Viral Hepatitis

Funding Opportunity: Pharyngeal Gonorrhea Test of Cure...

NACCHO will fund up to 4 local health departments (LHDs) up to $100,000 each to...

Jan 19, 2021 | Rebekah Horowitz

Funding Opportunity: Pharyngeal Gonorrhea Test of Cure...

Capitol Building
  • Press Release
  • Immunization

NACCHO Statement on President-Elect Biden’s American...

NACCHO’s Statement on President-Elect Biden’s American Rescue & Vaccine Plans...

Jan 19, 2021 | Andrea Grenadier

NACCHO Statement on President-Elect Biden’s American...

Doctor 563428 640
  • COVID-19
  • Health in All Policies
  • Leadership
  • Workforce Development

Preparing Your Local Health Department for the Future

If the pandemic has taught us one thing, it is the importance of preparedness....

Jan 15, 2021 | Guest Author

Preparing Your Local Health Department for the Future

Covid
  • COVID-19
  • Immunization

Dosing intervals for COVID-19 mRNA Vaccine

On January 6, CDC revised Interim Clinical Considerations for Use of mRNA...

Jan 14, 2021 | Beth Hess

Dosing intervals for COVID-19 mRNA Vaccine

  • Opportunity

APHA 2021 Call for Abstracts is Open

Submit an abstract to present and share research with public health leaders and...

Jan 13, 2021 | Anu Varma

APHA 2021 Call for Abstracts is Open

CRC Sim PLER
  • Webinar
  • Emergency Response

CRC SimPLER: A Practice Workshop

To introduce CRC SimPLER, ASTHO and the National Alliance for Radiation...

Jan 11, 2021 | Beth Hess

CRC SimPLER: A Practice Workshop

Coronavirus COVID 19
  • COVID-19
  • Tools & Resources
  • Epidemiology

COVID-19 Genomic Epidemiology Toolkit

The CDC Office of Advanced Molecular Detection (AMD) recently released the...

Jan 11, 2021 | Beth Hess

COVID-19 Genomic Epidemiology Toolkit

Back to Top